Articles related to ALZHEIMER'S/DEMENTIA

Prior research showed that higher flavonol consumption was associated with lower Alzheimer’s risk. This longitudinal study demonstrated that increased flavonol consumption yielded slower declines in global cognition and in episodic, semantic, and working memory, independent of other health and lifestyle factors.

Gantenerumab treatment generated a slowing of clinical decline from baseline score on the Clinical Dementia Rating-Sum of Boxes (CDR-SB), but at levels that did not reach statistical significance. The relative reduction in clinical decline was 8% in GRADUATE I and 6% in GRADUATE II compared with placebo.

At the time of this study, in 2016, dementia was seen in 10% of those over age 65 in the US, and mild cognitive impairment (MCI) in 20%, with increased risk for every 5 year advance in age. Risk was 80% higher for non-Hispanic Black individuals and approximately 40% higher in Hispanic persons, compared with White individuals. Dementia and MCI were inversely correlated with years of education, though.

The findings point to the possibility of very early detection of dementias, when recruitment into preventive trials, drug trials, and implementation of preventive strategies to slow the disease have the most impact.

In the confirmatory trial, Clarity AD, of 1,795 patients with early AD, findings showed a reduction of dementia scoring of 27% vs. placebo. These findings were seen as early as 6 months.

Palliative care (PC) can help reduce emergency department use, hospitalizations, and symptom burden across a spectrum of diseases. To assist clinicians in keeping their expertise current, the authors reviewed and summarized the top PC articles of 2020. The analysis included 28 PC intervention trials for heart failure, chronic obstructive pulmonary disease, and dementia.